🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.

Recruitingn/aAges 18 Years - 80 YearsAllCentre Hospitalier Universitaire de Besancon
NCT07833696 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study is sponsored by the University Hospital of Besancon under the coordination of Dr. Julie Castagna from the Department of Dermatology and Allergology. Approximately ten percent of patients with severe chronic urticaria remain refractory to standard or optimized biologic therapy, and this observational multicenter retrospective project aims to thoroughly evaluate these challenging cases. By analyzing a target population of seventy adult participants across French hospitals, the research focuses on identifying specific clinical and biological traits, outlining risk factors associated with non-response to high-dose treatment regimens, and documenting the alternative therapeutic strategies that follow treatment failure. Data collection is structured retrospectively to cover the period from January 2020 through the end of December 2026, leveraging existing medical records without impo

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with severe chronic urticaria resistant to optimized OMALIZUMAB (600 mg every 2 weeks) with an UCT score \< 6 or less than 50% clinical improvement according to the investigator's assessment. * Men and women aged 18 to 80 years inclusive. * Subjects who do not object to the use of their personal data and/or biological samples. * Affiliation with or beneficiary of a French social security scheme. Exclusion Criteria: * description of the characteristics and management of patients with severe chronic spontaneous and/or inducible urticaria experiencing failure of treatment with optimized omalizumab * patients with severe chronic urticaria resistant to optimized omalizumab (600 mg every 2 weeks) with an uct score \< 6 or less than 50% clinical improvement according to the investigator's assessment * men and women aged 18 to 80 years inclusive * subjects who do not object to the use of their personal data and/or biological samples * affiliation with or beneficiary of a french social security scheme
💊

What it tests

  • drug effect
📍

Where

1 site
CHU Minjoz BESANCON
Besançon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy